Psyence Group

Human longevity is shifting from a scientific pursuit to a global movement that challenges how we think about aging. In this opinion piece, Jody Aufrichtig, CEO of Psyence BioMed, explores why nature derived psychedelic compounds, especially psilocybin, may hold the key to one of the most significant breakthroughs in modern biology. Instead of treating aging as an unavoidable decline, he argues that we are entering a period where its underlying processes can be understood and influenced. Early research suggests that psilocybin may affect inflammation, oxidative stress, neuroplasticity, and cellular resilience, which are central to biological aging. Psyence BioMed has launched the first publicly listed psilocybin longevity research initiative to examine these effects with scientific rigor. The goal is not only to extend life, but to expand human potential through approaches that integrate psychological wellbeing, cellular health, and brain function as one interconnected system.